The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
Open Access
- 27 December 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Abstract
The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castration-resistant prostate cancer were analysed. Simulations were performed for different combinations of association rates kon (0.1–0.01 L/nmol/min), dissociation rates koff (0.1–0.0001 min−1), internalization rates λint (0.01–0.0001 min−1) and ligand amounts (1–1000 nmol). For imaging the activity was normalized to volume and injected activity (68Ga-PSMA at 1 h). For therapy the absorbed dose was calculated for 7.3 ± 0.3 GBq 177Lu-PSMA. The effect of the investigated parameters on therapy were larger compared to imaging. For imaging, the combination of properties leading to the highest tumour uptake was kon = 0.1 L/nmol/min, koff = 0.01 min−1 for typical ligand amounts (1–10 nmol). For therapy, the higher the internalization rate, the larger was the required ligand amount for optimal tumour-to-kidney ratios. The higher the affinity, the more important was the choice of the optimal ligand amount. PBPK modelling provides insight into the pharmacokinetics of PSMA-specific ligands. Further in silico and in vivo studies are required to verify the influence of the analysed parameters.Keywords
Funding Information
- LPDP-Lembaga Pengelola Dana Pendidikan
- Deutsche Forschungsgemeinschaft (GL236/11-1, SFB824 Project B11, KL2742/2-1)
This publication has 21 references indexed in Scilit:
- Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applicationsBiopharmaceutics & Drug Disposition, 2016
- Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingEJNMMI Research, 2016
- Design of Internalizing PSMA-specific Glu-ureido-based RadiotherapeuticalsTheranostics, 2016
- Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic AgentTheranostics, 2016
- Optimized Peptide Amount and Activity for 90Y-Labeled DOTATATE TherapyJournal of Nuclear Medicine, 2015
- PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate CancerJournal of Nuclear Medicine, 2015
- PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusTheranostics, 2015
- Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Molecular determinants of drug–receptor binding kineticsDrug Discovery Today, 2013
- A Systems Approach for Tumor PharmacokineticsPLOS ONE, 2011